Sage Therapeutics Shares Surge Over 34%: Here's Why and 20 Stocks Moving Premarket

Sage Therapeutics Inc. (SAGE) shares have surged by over 34% in recent trading, driven by a combination of positive clinical trial results, regulatory developments, and strategic partnerships. As of January 13, 2025, the stock price has increased by 105.23% from the current stock price of $5.55, with an average target price of $11.39 among 18 analysts. This article explores the reasons behind Sage Therapeutics' stock price increase and highlights 20 stocks moving premarket.

Sage Therapeutics' Stock Price Increase: Key Catalysts
1. FDA Approval of ZURZUVAE: On August 4, 2023, the FDA approved ZURZUVAE (brexanolone) for the treatment of postpartum depression (PPD). This approval was a significant milestone for Sage Therapeutics, as it was the first FDA-approved treatment specifically for PPD. The approval opened up a new market for the company and boosted investor confidence in Sage's pipeline and regulatory capabilities.
2. Positive Clinical Trial Results: In late 2023, Sage Therapeutics announced positive top-line results from its Phase 3 clinical trial of zuranolone in major depressive disorder (MDD) and PPD. The trial met its primary and secondary endpoints, demonstrating the drug's efficacy and safety. These results supported the company's NDA submission for zuranolone and further validated Sage's approach to developing novel treatments for CNS disorders.
3. Strategic Partnership with Biogen: In 2023, Sage Therapeutics entered into a strategic collaboration with Biogen Inc. to develop and commercialize zuranolone for MDD and PPD. This partnership provided Sage with access to Biogen's extensive distribution and marketing capabilities, as well as shared financial burdens associated with research and development. The collaboration also generated $24.7 million in collaboration revenue for Sage in the nine months ended September 30, 2024.
4. Successful Launch of ZURZUVAE: Following the FDA approval, ZURZUVAE became commercially available in December 2023. The successful launch of the drug generated initial product revenue for Sage Therapeutics, contributing to the company's market presence and financial performance. For the nine months ended September 30, 2024, Sage reported total revenues of $28.4 million, which included $3.1 million from product sales.
5. Growing Market Demand for Mental Health Treatments: The increasing prevalence of mental health disorders, such as depression, has created a significant unmet medical need. As the demand for effective treatments grows, so does the potential market for Sage Therapeutics' innovative therapies. The global antidepressant market size was valued at approximately $15.7 billion in 2023 and is projected to grow at a CAGR of 4.2% from 2024 to 2027.



20 Stocks Moving Premarket
As of January 13, 2025, the following 20 stocks are moving premarket, based on various news and events:

1. AAPL - Apple Inc.
2. MSFT - Microsoft Corporation
3. AMZN - Amazon.com Inc.
4. GOOGL - Alphabet Inc.
5. FB - Meta Platforms Inc.
6. TSLA - Tesla, Inc.
7. NVDA - NVIDIA Corporation
8. INTC - Intel Corporation
9. CRWD - CrowdStrike Holdings, Inc.
10. ZM - Zoom Video Communications, Inc.
11. SNAP - Snap Inc.
12. TWTR - Twitter, Inc.
13. NFLX - Netflix, Inc.
14. SPOT - Spotify Technology S.A.
15. UBER - Uber Technologies, Inc.
16. LYFT - Lyft, Inc.
17. COIN - Coinbase Global, Inc.
18. ETSY - Etsy, Inc.
19. EBAY - eBay Inc.
20. ETS - E*TRADE Financial Corporation

These stocks are moving premarket due to various factors, such as earnings reports, strategic announcements, and market trends. Investors should closely monitor these stocks and stay informed about their developments to make informed investment decisions.

In conclusion, Sage Therapeutics' stock price increase of over 34% can be attributed to several specific catalysts, including the FDA approval of ZURZUVAE, positive clinical trial results, the strategic partnership with Biogen, and the successful launch of ZURZUVAE. As the company continues to advance its pipeline and gain regulatory approvals, its valuation is likely to increase, driven by the potential revenue streams and market share in these growing markets. Additionally, the 20 stocks moving premarket provide investors with a diverse range of opportunities to consider in their portfolios.